Introduction. Prostatic infarction has been reported in 85% of those undergoing retropubic prostatectomy following presentation with acute urinary retention (AUR) (Spiro et al. Urology 1974: 3: 345 ± 347) . We sought to review the histological appearances seen in specimens taken at TURP following an episode of acute urinary retention, elective TURP and retropubic prostatectomy.
Patients and Methods. The pathological specimens from three groups undergoing prostatectomy were reviewed by a single pathologist (JT): Group 1, 27 patients who underwent TURP following an episode of AUR; Group 2, elective TURP, 20 patients; Group 3, retropubic prostatectomy, 13 patients. The extent of prostatic infarction and in¯ammation were assessed and compared.
Results. Groups 1 and 3 were signi®cantly older than Group 2 (mean ages 72.4 and 73.1 y vs 68.4 y, P`0.05) and the mean resected weight differed signi®cantly between all three groups (21 g; 9.5 g; and 73 g, P`0.001). There was no signi®cant difference in the prevalence of prostatitis between the groups, and true prostatic infarction was uncommon. A previously undescribed histological pattern which we have called`lobular necrosis' was seen more often within Groups 1 and 3 than in Group 2, and had a signi®cant association with larger prostate glands. It is characterised by inspissated secretions within glands and necrosis of their epithelial lining; the adjacent stroma is unaffected (unlike true infarction).
Conclusions. Prostatitis is very common in all resected prostate tissue but true infarction is rare.`Lobular necrosis' is common in larger glands and has an association with acute urinary retention. It has not been described previously, but it is possible that it may have been included with cases of true infarction in the past. We believe that`lobular necrosis' is not a primary vascular event and is therefore not true infarction. The aetiology and signi®cance of this histological pattern is discussed.
Introduction and Objectives. The aim of the study was to evaluate the long term ef®cacy of laser ablation of the prostate (using free beam technique) and its associated morbidity.
Material and Methods. Between November 1992 and November 1995, we carried out a prospective study on 170 patients with symptomatic (benign prostatic hyperplasia (BPH). The age range was 51 ± 87 y (mean 64.9 y). Prior to commencing therapy, a sextant prostatic biopsy was performed in all patients. Nd-Yag laser energy was delivered using a side ®ring 1000 micron quartz ®bre (Prolase II & I). Energy was delivered at 60 W for 60 s at various sectors, achieving deep coagulation necrosis. The post-operative catheterisation period was seven days. The mean prostatic volume was 34.4 g. (Range 22 ± 64) and the mean laser energy delivered was 36102 J.
Early complications at three months were irritative symptoms 24 patients (14%), urinary tract infection (UTI) 14(8.2%) haematuria 8 (4.7%), retention 7 (4.1%), stress incontinence 2 (1.2%), and perineal pain 2 (1.2%). Late complication at six months were bladder neck sclerosis 2 patient (1.2%) and stricture urethra 1 (0.6%). Out of 67% patients who were sexually active 34% reported retrograde ejaculation. Mean hospital stay was 1.6 days (range 1 ± 3). Reoperation rate was 8 patients (4.7%, 60% b 50 g) ®rst year, 2 (1.4%) second, 2 (2%) third, 2 (3.2%) fourth and 1 (2.8%) ®fth.
Conclusions. The only signi®cant morbidity was irritative symptoms (14%). Five year follow up results now illustrated that ELAP is very safe, durable and has a low reoperation rate in prostatic adenoma 50 g. Benign prostatic hyperplasia (BPH) is an age-related proliferative disorder occurring predominately in the stromal compartment of the prostate. Fibroblast growth factor (FGF2) and members of the transforming growth factor-b (TGFb) family are believed to be major determinants of growth in this compartment. We, and others, have shown that FGF2 and TGFbs 1, 2 and 3 are expressed in normal prostate and BPH tissue. Cultures of prostatic stromal cells also express these growth factors. In several studies FGF2 has been shown to be mitogenic and TGFb1 growth inhibitory (both at concentrations above 1 ng/ml) in prostatic stromal cells cultured in media containing serum.
We have recently re-examined the effects of these growth factors in cultures of prostatic stromal cells obtained from BPH tissue grown in serum free, de®ned medium (DCCM-1). Using this system we have shown that these cells are crucially dependent on FGF2 for growth and survival. Addition of TGFb1 at low concentrations enhances the growth promoting effect of FGF2. At higher concentrations (5 ng/ml) TGFb1 completely abrogates the growth promoting effects of FGF2. This observation is in line with the effects of TGFb1 at concentrations greater than 1ng/ml observed in standard tissue culture medium with serum.
When stromal cells were cultured in DCCM-1 with FGF2 and an antibody raised against TGFb1, cell numbers decreased relative to the controls. Detection of apoptosis by¯ow cytometry, using FITC-labelled annexin V, showed that treatment with anti-TGFb1 increases the proportion of cells in apoptosis compared with controls.
Together, these observations suggest a potentially complex mode of action for TGFb1 in the prostatic stromal compartment involving concentration dependent effects on growth and on apoptosis and interactions with FGF signalling pathways. Research into benign prostatic hyperplasia (BPH) is limited by the lack of well-characterised in vitro models. This study is an attempt to combine a functional and immunocytochemical approach to the characterisation of prostate stromal cells (PrS6) derived from a patient with BPH. Cells in culture were stained for smooth muscle-speci®c proteins. Evidence, in cultured cells, of functional a1-adrenoceptors, which mediate prostate smooth muscle contraction (Ghu et al, 1995) , was obtained by the measurement of intracellular calcium concentration [Ca 2 ] i in response to stimulation by the a1-adrenoceptor agonist, phenylephrine.
The life-span of the PrS6 cells was extended by retroviral transduction with a temperature-sensitive mutant of the SV40 T-antigen, tsA58-U19 (Stamps et al, 1994) . The cells were grown throughout on glass coverslips in DMEM medium (Imperial, UK) with 10% fetal calf serum (Sigma, UK).
Immuno¯uorescence was used to detect the presence of smooth muscle a-actin, smooth muscle heavy chains and desmin in the cells. Predicting subsequent carcinoma in patients with prostatic intraepithelial neoplasia R Thilagarajah, CM Allen, C Amerasinghe, MJ Gleeson, HN Whit®eld and E Rogers Departments of urology and histopathology, Central Middlesex Hospital, Acton Lane, Park Royal, London NW10 7NS
Detecting prostatic intraepithelial neoplasia (PIN) and atypical epithelium in prostatic biopsies without concur-rent cancer, engenders clinical concern. Occult adenocarcinoma can co-exist with or evolve from atypical epithelium. High grade PIN is a recognised premalignant condition, and clinical follow up with repeated prostatic biopsy is mandatory. Controversy surrounds the signi®-cance and clinical follow up of patients with low grade PIN or atypical epithelial histology. We adopted a policy of scheduled repeat biopsy in all patients with PIN and atypical prostatic epithelium, and we report our results to date.
From 1/8/1995 to 30/9/1998, 836 patients underwent random sextant transrectal ultrasound guided prostate biopsies. We identi®ed 45 patients with PIN and atypical histology without concurrent cancer, followed with repeat biopsies on at least two occasions (median interval = 184 days; range 30 ± 391). Patient age, digital rectal examination, serum prostate speci®c antigen (PSA), ultrasound appearance and PSA density (PSAD) at the time of initial biopsy were analysed for correlation with subsequent diagnosis of cancer.
Initial prostatic histology showed low grade PIN-25 patients; high grade PIN-10 patients, and indeterminate atypical epithelial proliferation-10 patients. Nine patients had carcinoma on subsequent biopsy (4 (16%) initial low grade PIN; 2 (20%) initial atypical epithelium; 3 (30%) initial high grade PIN). Serum PSA ( b 10ng/ml) and PSAD ( b 0.3) correlated signi®cantly with cancer detection (ANOVA P`0.05). However, these parameters had low speci®city for predicting cancer development in individual patients.
In conclusion, Repeat prostatic biopsy is the only reliable method of detecting subsequent cancer in patients with all grades of atypical morphology on initial biopsy.
Up-regulation and altered cellular distribution of COX-2 in human prostate cancer S Madaan 1,2 , EN Lalani 1 , KS Chaudhary 1 , GWH Stamp 1 and PD Abel 2 1 Department of Histopathology, Imperial College School of Medicine, Hammersmith Hospital Campus, London, UK and 2 Department of Surgery, Imperial College School of Medicine, Hammersmith Hospital Campus, London, UK Introduction. Cyclooxygenases (COXs) are enzymes involved in the conversion of arachidonic acid to prostaglandins (PG). A tendency towards reduced risk of advanced prostate cancer (PC) has been reported with regular use of non-steroidal anti-in¯ammatory drugs (they act by inhibiting COX). The proposed mechanisms to account for this apparent protection include: (a) induction of apoptosis; (b) reduced mitogenesis; (b) reversal of PG mediated immunosuppression. COX has two isoforms: COX-1, which is constitutively expressed and COX-2, which is inducible and shown to be up-regulated in various cancers. The aim of our study was to determine the expression pro®le of both COX-1 and 2 proteins in benign prostatic hyperplasia (BPH) and PC using immunohistochemistry (IHC) and immunoblotting.
Materials and Methods. 30 BPH and 82 PC formalin®xed paraf®n-embedded samples were serially sectioned (4 micron) onto silane-coated slides. Sections were microwaved at 750 W for 15 min in citrate buffer (pH 6.0) and subjected to IHC with COX-1 and COX-2 speci®c mouse monoclonal antibodies (Cayman Chemicals). Western blotting was performed on a total of 13 fresh frozen samples (6 BPH and 7 PCs) and probed with COX-1 or COX-2 mouse monoclonal antibody.
Results. (a) BPH: Heterogeneous ®ne granular cytoplasmic COX-1 expression was found predominantly in ®bro-muscular stroma in all samples with occasional weak expression in glandular epithelium. Only the luminal glandular cells showed membranous COX-2 expression. (b) PC: Stromal expression for COX-1 and COX-2 remained unaltered. There was variable weak cytoplasmic expression of COX-1 in tumour cells. A signi®cant increase (P 0.008) in COX-2 expression was observed in tumour cells with an appreciable change in staining pattern from membranous to cytoplasmic (P 0.001). There was also a signi®cant increase (P 0.01) in the intensity of COX-2 expression in high grade (poorly differentiated) cases as compared to low grade (well differentiated).
On immunoblotting up to 4-fold increased expression of COX-2 was detected in PCs as compared to BPH, while COX-1 levels were similar in both. Conclusion. COX-2 is constitutively expressed in luminal prostatic epithelial cells while in cancer cells its expression increases and localisation changes showing a direct correlation with increasing tumour grade. These results suggest that COX-2 may contribute to the differentiation state of the prostatic adenocarcinoma.
The role of analgesia in TRUS and biopsy
A Haq, S Mattocks, R Batstone and C Dawson Edith Cavell Hospital, Peterborough, UK.
Introduction. TRUS and biopsy is now a routine step in the diagnosis of prostatic disease, especially neoplasia. Although it is well recognised to be associated with pain TRUS and biopsy is routinely performed without analgesia. We prospectively compared the use of analgesia with the standard practice of no analgesia in consecutive randomised patients undergoing TRUS and biopsy.
Patients and Methods. A prospective randomised study was performed wherein 50 patients were randomised to either with or without analgesia. All patients having the procedure on one particular day were placed in one group i.e. all were or were not given analgesia. The patients were asked to indicate on a visual analogue scale (VAS, maximum score 10) directly after the procedure, the degree of pain they had experienced.
All TRUS were performed by the same operator (AH) using a B & K Medical Type 2003 Ultrasound Machine and a Bard biopsy gun with an 18 g trucut needle. Any patient who had more than the standard sextant biopsy was excluded from the study. The method of analgesia was Voltarol 100 mg PR administered with antibiotic prophylaxis (750 mg cipro¯oxacin PO) 1 hour prior to the procedure.
Results. The mean pain scores for those patients who were not provided with analgesia were 3.0 (range 0 ± 7) and those for patients with analgesia were 2.1 (range 0 ± 5.8) the difference being statistically signi®cant (P 0.05).
Conclusion. It is surprising that for a procedure which has become common in urological practice the need or otherwise for analgesia has not been assessed by a prospective randomised controlled trial. Our pilot study indicates that patients derive bene®t from PR Voltarol and we plan to conduct further studies comparing different types of analgesia. Aims. In order to assess their role in prostate disease our aim is to identify epithelial stem cells in prostate tissue and to establish ways of isolating them. Here we will present the identi®cation of sub-populations of basal epithelial cells, based on the expression of different keratins, that allows us to speculate on the differentiation state of different basal cells.
Characterisation of a human prostate epithelial-cell differentiation pathway
Methods. Both paraf®n embedded and frozen tissue sections of TURP prostate tissue were stained for expression of keratin subunits 5, 7, 8, 14, 15, 17, 18 and 19 and additionally for Ki67, a marker for cycling cells. Prior to staining, paraf®n sections underwent microwave antigen retrieval and this allowed us, for the ®rst time, to use simultaneous immuno¯uorescent detection of multiple antigens in ®xed, embedded tissue. Using IgG subclass speci®c secondary antibodies it is possible to stain sections with up to four different primary antibodies and use secondary antibodies which are detected at the blue, green, red and far-red wavelengths.
Results. Basal epithelial cells have previously been shown to express keratins K5/14, with luminal cells expressing K8/18. Using triple immuno¯uorescent staining of tissue sections with isotype speci®c monoclonal antibodies we have found that the basal layer actually has several different keratin patterns. Co-staining for K14 and K19 shows three types of expression: some cells have K14 only, some K19 only and others both together. K19 is also found in a subgroup of luminal cells and we believe that this represents a differentiation pathway from K5/14 alone to K8/18 alone with K19 expressed by intermediate cell types. Ki67 can be co-expressed with any of the keratins, with the highest percentage expressing K14 (47.7%, n 10) and the lowest K18 (9.4%, n 5).
Conclusions.
We have used a novel staining method that has allowed us to study keratin co-expression in epithelial cells of the basal and luminal prostate cell layers. We ®nd that keratin 19 is a marker for cells undergoing differentiation, since it is expressed by cells in both layers, while K14 is expressed by less differentiated cells and found alone may be a marker for a stem cells population.
Getting closer to the prostate? Replacing prostate cell lines with organ culture for the optimisation of targeted gene expression To test the potential for targeted gene therapy of prostate cancer, we have generated a series of recombinant adenoviruses which express the Green Fluorescent Protein (GFP) under the control of both prostate-speci®c and strong viral promoters. When assayed in tissue culture cells the levels of GFP can be determined by (i) Visual inspection of the living cells over a period of up to ®ve days by phase microscopy Ð This can now be quanti®ed, using Openlab software; (ii) Extraction of the cells and western blotting with an antibody against the GFP; and (iii) Fluorescence activated cell sorting analysis. The results are consistent in magnitude and speci®city of expression.
Unsurprisingly, native promoters from prostate speci®c genes such as PSA and PSMA are not absolutely prostate speci®c. Rather, they show signi®cantly higher levels of expression than in other tissues. Also cell lines derived from other tissues are frequently not representative of the tissues, particularly if they are from tumour tissues. For example a common breast carcinoma cell line T47D expresses the highest levels of both PSA and PSMA that we have seen in the laboratory! By manipulating the DNA sequences in the promoters, we can enhance (or destroy) the tissue speci®city of thè prostate-speci®c' promoters. This also frequently results in a diminution of the strength of the promoters in tissue culture cells. However, preliminary studies with primary cultures from prostate tissues indicated that higher levels of expression from the manipulated promoters could be achieved, the closer the test cells were to the original tissues.
A better assay is to move even closer to tissues by using thick slices of prostate tissues, maintained in vitro over a ®ve day period. We have developed the conditions to enable infection of these mini-organs with the recombinant adenoviruses to test this hypothesis. Tissues are infected on day 0 about 8 ± 14 hours after placing the tissues in culture in multi-chamber slides. After visual inspection under inverted phase ultraviolet illumination, the green¯uorescence can be observed on day 1, between 8 and 16 hours after infection. In contrast to the cell cultures, where the viral promoters were between 10 and 100 times stronger than the prostate promoters, in organ culture there is very little difference in promoter strength. However, there is a striking cell speci®city observed in the tissue slices, which can be further studied by removal and frozen sectioning of the tissues. Glandular areas can clearly be differentiated from the H&E or immunostaining patterns, and related to the GFP positive areas. The results indicate that the PSA and PSMA promoters target GFP expression to glandular epithelium, with a striking sub-localisation in normal glands but not in tumours. In contrast, the cytomegalovirus (CMV) promoter is preferentially active in mesenchymal cells.
The system is more representative of prostate tissue than xenograft models, and considerably more rapid. It offers a contained and controllable technique to study gene targeting in the therapy of prostate cancers.
Neoadjuvant androgen blockade in T1 and T2 Prostate carcinoma Histopathology and PSA-failure after radical prostatectomy The aim of this study was to assess the relationship between PSA failure and histopathological ®ndings in radical prostatectomy specimens following neoadjuvant androgen blockade (NAB) and to identify possible risk factors for PSA failure.
Methods. A retrospective analysis of 134 radical prostatectomies after three months of NAB with a mean follow-up of 23.5 months ( AE 16.3 s.d.) (range 3 ± 60). We also analysed a subgroup of 60 patients with a minimum follow-up of 24 months (mean 38.9 AE 10.1 s.d.).
Potential risk factors assessed were: positive lymph nodes or seminal vesicles, positive surgical margins, prostate capsule involvement by invasion or penetration, perineural invasion, Gleason score ! 7 in biopsy or prostatectomy specimen and PSA at presentation.
Results. PSA failure occured in 6 of 9 lymph node or seminal vesicle positive patients (P`0.001). Prostate capsule invasion without penetration (P`0.02) and capsule penetration (P`0.05) were both signi®cant risk factors for PSA failure in the remaining patients, as was a biopsy Gleason score ! 7 (P`0.02). None of the other factors were signi®cant risk factors. These ®ndings were qualitatively the same on analysing the subgroup with 24 months minimum follow-up (P`0.01 for capsule invasion without penetration, P`0.02 for capsule penetration, P`0.02 for biopsy Gleason ! 7). Prostate cancer (PC) is an escalating health burden for the Western world and the second most common cause for cancer Ð related deaths in males. The most important clinically signi®cant change is the development of androgen independence (AI) in PC. Androgen receptor (AR) gene loss, mutations or ampli®cation contribute towards the development of AI in PC. Also, de novo expression of an anti-apoptotic protein Bcl-2 has been reported to be closely associated with AI state in PC. Development of AI and underlying molecular changes are not fully understood but it is important to establish the role of Bcl-2 in prostatic cell cycle/death regulation and its relationship to the emergence of AI-PC.
We have generated a novel in-vitro model of PC from the DU145 human prosatic adenocarcinoma cell line that mirrors the biological spectrum of clinical disease in man. Mammalian expression vectors encoding Bcl-2 (pBabe/ bcl-2) and AR (pcAR3.1) were constructed for gene transfections into the DU145. Utilising calcium phosphate and liposomal gene transfection methodologies, we have generated a panel of cell lines expressing Bcl-2, AR or both. Expression of these has been analysed by RT-PCR, Western blotting and immunohistochemistry.
Bcl-2 expression did not affect the cellular growth under standard culture conditions. Bcl-2 expressing clones showed decreased levels of p53 and increased levels of PCNA and Bax proteins compared to controls. Bcl-2 expression conferred a 10-fold increase in cytotoxic chemo-resistance against adriamycin and thapsigargin. AR transfectants expressed an androgen responsive and functional AR. 5 nM dihydrotestosterone treatment resulted in rapid nuclear translocation of AR. Transcriptional activity of the AR was con®rmed by its ability to transactivate MMTV-luciferase reporter plasmid in dihydrotestosterone (DHT) dependent manner. AR transfectants also exhibited DHT dependent decreased cellular proliferation (up to 40%) and increased apoptosis (up to 2-fold). Co-transfectants expressing both Bcl-2 and AR simultaneously did not exhibit above responses to DHT treatment. Moreover they also exhibited a similar cytotoxic chemo-resistance against adriamycin and thapsigargin.
The development of an in-vitro model simulating biology of PC progression in vivo will facilitate our understanding of some of the underlying mechanisms governing AI in PC.
Anti-GnRH antibodies for treatment of advanced prostate cancer Ð initial experience MS Simms and MC Bishop Department of Urology, City Hospital, Nottingham, UK Introduction Gonadimmune 1 (Aphton Corporation, California, USA) consists of the GnRH decapeptide linked to diptheria toxoid. Immunisation of rabbits with Gonadimmune 1 has been shown to induce anti-GnRH antibodies with subsequent disruption of the hypothalamic/gonadal/pituitary axis and a resultant castrate state. This pilot study aimed to investigate the tolerance and ef®cacy of two doses of Gonadimmune 1 in patients with advanced prostate cancer.
Method The study was approved by the local Ethics Committee. Two groups of six patients with advanced prostate cancer were recruited. The ®rst group received three intramuscular injections of 30 mg of Gonadimmune 1 at 0, 2, and 6 weeks. The second group received 3 6 100 mg injections. Patients were followed up at two weekly intervals and blood was taken for estimation of serum testosterone, PSA and anti-GnRH antibody titre.
Results Injection site reactions were mild. All patients developed anti-GnRH antibodies during the course of the study and in ®ve patients a signi®cant reduction in serum testosterone and PSA was seen. This lasted for at least six months and castrate levels of testosterone are maintained in four patients. Follow-up continues on these patients.
Discussion Anti-GnRH antibodies secondary to immunisation with Gonadimmune 1 can induce castrate levels of testosterone in patients with advanced prostate cancer. At present it is unclear why some patients respond better than others. If successful however, this novel form of hormonal therapy produces a lasting response from just three intramuscular injections. The doses used in this study can be regarded as small and an increase in dosage or alteration of injection schedule may produce a castrate response in a greater proportion of patients. Further studies are underway to address these factors. Prostate cancer (PC) is the second most common cause of cancer-related death in men in the Western world. Prostatic adenocarcinoma cells are androgen dependent and elimination or reducing endogenous androgens by surgical or chemical castration results in both subjective and objective improvement in patients with PC but only lasts for a median time of approximately two years. Relapse is due to evolution of androgen independent (AI) cell growth and there is little data on the molecular mechanisms underlying the progression to this state. E-cadherin is a member of the cadherin superfamily of cell adhesion molecules, is expressed in virtually all epithelial cells and has been shown to be down-regulated in invasive PC. Lower Gleason grade PCs express E-cadherin normally. The aims of this project were to: (1) develop an in vitro cell line model of PC; (2) determine the functionality of the AR; and (3) assess the effects of the AR on cell adhesion.
A plasmid containing the full length cDNA encoding the AR was transfected into the AI PC cell line DU-145. Three transfectants were developed, DAR 17 and DAR 19 which expressed a cytoplasmically localised AR of 110 kDa and Dzeo1, a negative control. Transcriptional activity of the AR was con®rmed by its ability to transactivate the AR responsive plasmid MMTV-luciferase in a dihydrotestosterone (DHT) dependent manner.
Growth of DAR 17 and DAR 19 in normal culture conditions resulted in a decrease in E-cadherin expression in DAR 17 and DAR 19 compared with Dzeo1 (40 ± 45% compared with 65 ± 70% of cells expressing cell surface E-cadherin) as detected by immunocytochemistry and FACS analysis. Addition of 5 nM DHT to the growth medium enhanced this reduction (only 30 ± 35% of cells expressing cell surface E-cadherin) and also resulted in decreased cell ± cell aggregation (from 65% to 30%). Immunoprecipitation data suggests that there is a disruption of the E-cadherin ± catenin interactions after exposure to DHT.
These results suggest that AR may regulate expression of E-cadherin in prostatic adenocarcinoma.
